-
公开(公告)号:US20230051523A1
公开(公告)日:2023-02-16
申请号:US17877535
申请日:2022-07-29
Applicant: Immatics Biotechnologies GmbH
Inventor: Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , C12N15/10 , C07K16/30 , C07K7/06 , G01N33/574 , A61K35/17 , C12N15/115 , C07K14/54 , C07K14/74 , C07K16/28 , A61K39/00 , C07K14/725 , C12N5/0783 , A61P35/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
512.
公开(公告)号:US20230051035A1
公开(公告)日:2023-02-16
申请号:US17937268
申请日:2022-09-30
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor: Toni WEINSCHENK , Jens FRITSCHE , Harpreet SINGH , Andrea MAHR , Martina OTT , Claudia WAGNER , Oliver SCHOOR
IPC: A61K39/00 , C07K14/47 , C07K14/74 , C07K16/18 , C12N15/115
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20230046543A1
公开(公告)日:2023-02-16
申请号:US17934673
申请日:2022-09-23
Applicant: Immatics Biotechnologies GmbH
Inventor: Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , C07K7/06 , A61K35/17 , C07K14/74 , C12N15/10 , C07K16/28 , G01N33/574 , C07K16/30 , C07K14/54 , C12N15/115 , C07K14/725 , C12N5/0783 , A61K39/00 , A61P35/00
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20230042461A1
公开(公告)日:2023-02-09
申请号:US17930914
申请日:2022-09-09
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: C07K14/74 , C07K14/47 , A61K39/00 , A61K51/10 , C07K14/705 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N15/115 , C12P21/02 , C12Q1/6881 , G01N33/569
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20230031307A1
公开(公告)日:2023-02-02
申请号:US17853334
申请日:2022-06-29
Applicant: Immatics Biotechnologies GmbH
Inventor: Toni WEINSCHENK , Andrea MAHR , Jens FRITSCHE , Phillip MUELLER , Anita WIEBE , Sarah KUTSCHER
IPC: A61K39/00 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/435 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12N15/115 , G01N33/68 , A61K51/10
Abstract: A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.
-
公开(公告)号:US20230002464A1
公开(公告)日:2023-01-05
申请号:US17929465
申请日:2022-09-02
Applicant: Immatics Biotechnologies GmbH
Inventor: Colette SONG , Heiko SCHUSTER , Daniel Johannes KOWALEWSKI , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , A61K35/17 , A61K39/00 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12Q1/6886
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20220387566A1
公开(公告)日:2022-12-08
申请号:US17358806
申请日:2021-06-25
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , C07K16/28 , C07K16/30 , C07K14/725 , G01N33/574 , C12Q1/6886 , A61P35/00 , C12N15/115 , C07K14/74 , C07K14/47 , C07K7/06 , C12N5/0783 , C07K7/08
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20220348622A1
公开(公告)日:2022-11-03
申请号:US17860827
申请日:2022-07-08
Applicant: Immatics Biotechnologies GmbH
Inventor: Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC: C07K14/47 , C07K14/74 , C07K16/30 , C07K14/725 , C12N5/0783 , C12N15/10 , A61K39/00 , C12N15/115 , G01N33/574 , A61P35/00 , C07K16/28 , A61K35/17 , C07K7/06 , C07K14/54
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号:US20220331413A1
公开(公告)日:2022-10-20
申请号:US17320763
申请日:2021-05-14
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K39/00 , C07K14/47 , A61P35/00 , C07K7/06 , C07K7/08 , C07K14/725 , C07K14/74 , C07K16/30 , C12N5/0783 , C12Q1/6886 , G01N33/574 , C07K16/28 , C12N15/115
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
520.
公开(公告)号:US20220323501A1
公开(公告)日:2022-10-13
申请号:US17837807
申请日:2022-06-10
Applicant: Immatics Biotechnologies GmbH
Inventor: Andrea MAHR , Toni WEINSCHENK , Anita WIEBE , Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Harpreet SINGH
IPC: A61K35/17 , A61K39/00 , C07K14/47 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , A61K35/16 , A61K39/39
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-